• Ascelia Pharma posted a Q2 operating loss of SEK 12.1 million, narrowing from SEK 23 million a year earlier.
• Loss per share improved to SEK 0.09 from SEK 0.20 in the prior-year quarter.
• Operating cash outflow totaled SEK 14 million, compared with SEK 18 million a year earlier; liquid assets and marketable securities fell to SEK 38 million.
• FDA issued a Complete Response Letter for Orviglance’s NDA; a Type A meeting is scheduled for Sept. 9.
• Cost-saving measures were launched to cut cash burn; management reiterated confidence in approvability backed by Phase 3 SPARKLE results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascelia Pharma AB published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.